Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 11/20 | 0.49 |
| ▸ | TCF7L2 | Q9NQB0 | 11/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13797220 | 0.86 | CTNNB1 (0.59) | MAPTTP53CTNNB1TCF7L2POLB | |
| SCHEMBL13797205 | 0.77 | CTNNB1 (0.68) | CTNNB1TCF7L2 | |
| SCHEMBL13333277 | 0.76 | PDPK1 (0.61) | MAPTTP53POLBPDPK1RXFP1 | |
| SCHEMBL13797208 | 0.76 | CTNNB1 (0.73) | CTNNB1TCF7L2 | |
| SCHEMBL13306397 | 0.75 | PDPK1 (0.62) | MAPTTP53POLBPDPK1RXFP1 | |
| SCHEMBL13797218 | 0.74 | CTNNB1 (0.53) | MAPTCTNNB1TCF7L2 | |
| SCHEMBL14309044 | 0.73 | PDPK1 (0.64) | MAPTTP53POLBPDPK1RXFP1 | |
| SCHEMBL13306405 | 0.73 | PDPK1 (0.64) | MAPTTP53POLBPDPK1RXFP1 | |
| SCHEMBL4989827 | 0.72 | MAPT (0.50) | MAPTTP53POLBPDPK1RXFP1 | |
| SCHEMBL14090925 | 0.70 | MAPT (0.51) | MAPTTP53POLBPDPK1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | MAPT 1454/4885TP53 4774/4885CTNNB1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.